Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soleno Therapeutics filings document the regulatory, financial, governance, and capital-structure disclosures of a Nasdaq-listed biopharmaceutical company commercializing VYKAT XR for hyperphagia associated with Prader-Willi syndrome. Recent Form 8-K reports cover operating results and launch updates, regulatory and marketing-authorization matters for diazoxide choline, material agreements, share-repurchase arrangements, and the company's common stock registration on Nasdaq.
The filing record also includes board-approved bylaw amendments, officer appointments and compensation arrangements, exhibits to earnings releases, and material-event disclosures related to strategic transactions. These documents formalize the company's public reporting around product commercialization, corporate governance, executive compensation, and risk-related business developments.
Soleno Therapeutics, Inc. files a post-effective amendment to deregister securities previously registered for resale and confirms termination of that registration following its merger into Neurocrine Biosciences.
The amendment states the Registration Statement covering an aggregate of 3,000,000 shares of common stock is being removed from registration and that all unsold or unissued securities under Registration No. 333-275120 are terminated as of May 21, 2026.
Soleno Therapeutics officer Kristen Yen reported disposing of all her company equity in connection with a cash merger. On May 18, 2026, 37,639 shares of Common Stock were surrendered to the issuer, leaving her with zero shares reported after the transaction.
Footnotes explain that, under an Agreement and Plan of Merger among Soleno Therapeutics, Neocrine Biosciences and a merger subsidiary, each share of Common Stock and each vested and unvested RSU was cancelled and converted into the right to receive $53.00 in cash per share. Multiple employee stock options, including grants covering 55,392 shares at an exercise price of $5.25 per share and 11,900 shares at $43.65 per share, were also cancelled in exchange for cash equal to their spread to the $53.00 merger consideration, so no options remain outstanding for Yen.
Soleno Therapeutics director Birgitte Volck reported the cancellation of her equity in connection with Soleno’s merger with Neurocrine Biosciences. She disposed of 17,536 shares of Common Stock to the issuer on May 18, 2026, with each share converted into the right to receive $53.00 in cash as merger consideration.
Previously granted restricted stock units were also cancelled and similarly converted into the cash consideration. Multiple stock option awards, including 10,000 options with a $5.25 exercise price, were cancelled in exchange for cash equal to $53.00 minus the exercise price, multiplied by the options’ share count. Following these transactions, the filing shows Volck with no remaining Soleno shares or options.
Soleno Therapeutics director Andrew Sinclair reported the disposition of his equity in connection with Soleno’s merger with Neocrine Biosciences. On May 18, 2026, 10,491 shares of Common Stock and multiple stock options were canceled as they were transferred back to the issuer.
Under the merger agreement, each share of Common Stock and each vested and unvested RSU was converted into the right to receive $53.00 in cash per share. Each stock option was canceled for a cash payment equal to the $53.00 merger consideration minus its exercise price, multiplied by the number of option shares.
Following these transactions, Sinclair reported holding zero shares of Soleno Common Stock and no remaining stock options in this filing.
Soleno Therapeutics director Matthew Pauls reported a merger-related cash-out of his equity stake. On May 18, 2026, he disposed of 10,491 shares of common stock and no shares remained directly held afterward.
In connection with the merger of Soleno with Sigma Merger Sub, making Soleno a wholly owned subsidiary of Neocrine Biosciences, each share of common stock and each vested and unvested RSU was cancelled and converted into the right to receive $53.00 in cash per share. A stock option covering 9,063 shares with a $4.60 exercise price was cancelled in exchange for a cash payment calculated as the difference between the $53.00 merger consideration and the exercise price, multiplied by the number of option shares.
Soleno Therapeutics’ Chief Business Officer Kevin Norrett reported dispositions tied to the company’s merger with Neocrine Biosciences. He surrendered 17,786 shares represented by previously reported RSUs and two stock option grants covering 4,000 and 64,286 shares of Common Stock.
In the merger, each RSU and each share of Common Stock was cancelled and converted into the right to receive $53.00 in cash per share, while each stock option was cancelled for a cash payment equal to its intrinsic value. Following these transactions, Norrett holds no directly reported Soleno common shares or related stock options in this filing.
Soleno Therapeutics' Chief Commercial Officer, Meredith Manning, reported the cancellation of her equity in connection with Soleno’s merger with Neurocrine Biosciences. On May 18, 2026, all of her 64,507 shares of common stock were disposed of back to the issuer and converted into a cash payment.
Footnotes explain that, under the merger agreement, each share of common stock and each vested or unvested RSU was cancelled and converted into the right to receive $53.00 in cash per share. Several employee stock option grants were also cancelled in exchange for cash equal to the spread between $53.00 and their exercise prices, multiplied by the number of option shares.
After these issuer dispositions, the filing shows no remaining common stock or options for Manning from these reported awards, reflecting the change from equity in Soleno to cash consideration at closing of the merger.
Soleno Therapeutics Chief Development Officer Manher Joshi disposed of his remaining equity in connection with Soleno’s merger into Neurocrine Biosciences. A total of 20,171 shares of common stock represented by restricted stock units were cancelled and converted into the right to receive $53.00 per share in cash. Two stock option grants covering 4,700 shares at $43.65 and 72,321 shares at $46.31 were also cancelled for cash payments based on the $53.00 merger price. Following these transactions, the filing shows no remaining common stock or options held directly by Joshi.